Mingming Yang

Dr. Mingming Yang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMingming Yang
Mingming Yang
ACAmy Elizabeth Chadwick
Amy Elizabeth Chadwick
CDCaroline Dart
Caroline Dart
TKTomoko Kamishima
Tomoko Kamishima
JQJohn M Quayle
John M Quayle
Bioenergetics of artery smooth muscle cells is critical in cardiovascular health and disease. An acute rise in metabolic demand causes vasodilation in systemic circulation while a chronic shift in bioenergetic profile may lead to vascular diseases. A decrease in intracellular ATP level may trigger physiological responses while dedifferentiation of contractile smooth muscle cells to a proliferative and migratory phenotype is often observed during pathological processes. Although it is now possible to dissect multiple building blocks of bioenergetic components quantitatively, detailed cellular bioenergetics of artery smooth muscle cells is still largely unknown. Thus, we profiled cellular bioenergetics of human coronary artery smooth muscle cells and effects of metabolic intervention. Mitochondria and glycolysis stress tests utilizing Seahorse technology revealed that mitochondrial oxidative phosphorylation accounted for 54.5% of ATP production at rest with the remaining 45.5% due to glycolysis. Stress tests also showed that oxidative phosphorylation and glycolysis can increase to a maximum of 3.5 fold and 1.25 fold, respectively, indicating that the former has a high reserve capacity. Analysis of bioenergetic profile indicated that aging cells have lower resting oxidative phosphorylation and reduced reserve capacity. Intracellular ATP level of a single cell was estimated to be over 1.1 mM. Application of metabolic modulators caused significant changes in mitochondria membrane potential, intracellular ATP level and ATP:ADP ratio. The detailed breakdown of cellular bioenergetics showed that proliferating human coronary artery smooth muscle cells rely more or less equally on oxidative phosphorylation and glycolysis at rest. These cells have high respiratory reserve capacity and low glycolysis reserve capacity. Metabolic intervention influences both intracellular ATP concentration and ATP:ADP ratio, where subtler changes may be detected by the latter.

30 September 2024 in JACC
Verified
Journal Article
Open access
MYMingming Yang
Mingming Yang
AHAlasdair D. Henderson
Alasdair D. Henderson
ATAtefeh Talebi
Atefeh Talebi
JAJohn J. Atherton
John J. Atherton
CCChern-En Chiang
Chern-En Chiang
JMJohn J.V. McMurray
John J.V. McMurray

12 May 2024 in JACC
Verified
Journal Article
Closed access
SMShingo Matsumoto
Shingo Matsumoto
AHAlasdair D. Henderson
Alasdair D. Henderson
LSLi Shen
Li Shen
MYMingming Yang
Mingming Yang
KSKarl Swedberg
Karl Swedberg
JMJohn J.V. McMurray
John J.V. McMurray

4 July 2019 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
Changye SunChangye Sun
Changye Sun
MLMengxin Liu
Mengxin Liu
PSPanwen Sun
Panwen Sun
MYMingming Yang
Mingming Yang
EYEdwin A. Yates
Edwin A. Yates
DFDavid Garth Fernig
David Garth Fernig
Fibroblast growth factors (FGFs) regulate embryonic development and homeostasis, including tissue and organ repair and specific aspects of metabolism. The basic FGF and acidic FGF, now known as FGF2 and FGF1, are widely used protein drugs for tissue repair. However, they are susceptible to denaturation at ambient temperatures and during long‐time storage, which will reduce their biological activity. The interaction of FGFs with the sulfated domains of heparan sulfate and heparin is essential for their cellular signaling and stability. Therefore, we analyzed the interactions of FGF1 and FGF2 with four sulfated polysaccharides: heparin, dextran sulfate (DXS), λ‐carrageenan, and chondroitin sulfate. The results of thermal stability and cell proliferation assays demonstrate that heparin, DXS, and λ‐carrageenan bound to both FGFs and protected them from denaturation. Our results suggest heparin, DXS, and λ‐carrageenan are potential formulation materials that bind and stabilize FGFs, and which may also potentiate their activity and control their delivery.

3 August 2023 in European Journal of Heart Failure
Verified
Journal Article
Open access
MYMingming Yang
Mingming Yang
TKToru Kondo
Toru Kondo
CACarly Adamson
Carly Adamson
JBJawad H. Butt
Jawad H. Butt
WAWilliam T. Abraham
William T. Abraham
JMJohn J.V. McMurray
John J.V. McMurray
Aim: Patients with heart failure (HF) often suffer from a range of comorbidities, which may affect their health status. The aim of this study was to assess the impact of different comorbidities on health status in patients with HF and reduced (HFrEF) and preserved ejection fraction (HFpEF). Methods and results: Using individual patient data from HFrEF (ATMOSPHERE, PARADIGM-HF, DAPA-HF) and HFpEF (TOPCAT, PARAGON-HF) trials, we examined the Kansas City Cardiomyopathy Questionnaire (KCCQ) domain scores and overall summary score (KCCQ-OSS) across a range of cardiorespiratory (angina, atrial fibrillation [AF], stroke, chronic obstructive pulmonary disease [COPD]) and other comorbidities (obesity, diabetes, chronic kidney disease [CKD], anaemia). Of patients with HFrEF (n = 20 159), 36.2% had AF, 33.9% CKD, 33.9% diabetes, 31.4% obesity, 25.5% angina, 12.2% COPD, 8.4% stroke, and 4.4% anaemia; the corresponding proportions in HFpEF (n = 6563) were: 54.0% AF, 48.7% CKD, 43.4% diabetes, 53.3% obesity, 28.6% angina, 14.7% COPD, 10.2% stroke, and 6.5% anaemia. HFpEF patients had lower KCCQ domain scores and KCCQ-OSS (67.8 vs. 71.3) than HFrEF patients. Physical limitations, social limitations and quality of life domains were reduced more than symptom frequency and symptom burden domains. In both HFrEF and HFpEF, COPD, angina, anaemia, and obesity were associated with the lowest scores. An increasing number of comorbidities was associated with decreasing scores (e.g. KCCQ-OSS 0 vs. ≥4 comorbidities: HFrEF 76.8 vs. 66.4; HFpEF 73.7 vs. 65.2). Conclusions: Cardiac and non-cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype. Treating/correcting comorbidity is a therapeutic approach that may improve the health status of patients with HF.

1 December 2010 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
BCBaoan Chen
Baoan Chen
WWWu Weiwei
Wu Weiwei
CJCheng Jian
Cheng Jian
WJWang Jun
Wang Jun
GFGao Feng
Gao Feng
JLJieyong Li
Jieyong Li
Purpose: The objectives of this research were to assess the biocompatibility of self-assembled Fe3O4 magnetic nanoparticles (MNPs) loaded with daunorubicin (DNR), ie, (Fe3O4-MNPs/DNR), and to explore their potential application in the treatment of hematologic malignancies. Methods: A hemolysis test was carried out to estimate the hematologic toxicity of Fe3O4-MNPs/DNR and a micronucleus assay was undertaken to identify its genotoxicity. Fe3O4-MNPs/DNR were injected intraperitoneally into mice to calculate the median lethal dose (LD50). The general condition of the mice was recorded, along with testing for acute toxicity to the liver and kidneys. Results: Hemolysis rates were 2.908%, 2.530%, and 2.415% after treatment with different concentrations of Fe3O4-MNPs/DNR. In the micronucleus assay, there was no significant difference in micronucleus formation rate between the experimental Fe3O4-MNPs/DNR groups and negative controls (P > 0.05), but there was a significant difference between the experimental groups and the positive controls (P > 0.05). The LD50 of the Fe3O4-MNPs/DNR was 1009.71 mg/kg and the 95% confidence interval (CI) was 769.11–1262.40 mg/kg, while that of the DNR groups was 8.51 mg/kg (95% CI: 6.48–10.37 mg/kg), suggesting that these nanoparticles have a wide safety margin. Acute toxicity testing showed no significant difference in body weight between the treatment groups at 24, 48, and 72 hours after intraperitoneal injection. The mice were all in good condition, with normal consumption of water and food, and their stools were formed and yellowish-brown. Interestingly, no toxic reactions, including instability of gait, convulsion, paralysis, and respiratory depression, were observed. Furthermore, alanine transaminase, blood urea nitrogen, and creatinine clearance in the experimental Fe3O4-MNPs/DNR groups were 66.0 ± 28.55 U/L, 9.06 ± 1.05 mmol/L, and 18.03 ± 1.84 µmol/L, respectively, which was not significantly different compared with the control and isodose DNR groups. Conclusion: Self-assembled Fe3O4-MNPs/DNR appear to be highly biocompatible and safe nanoparticles, and may be suitable for further application in the treatment of hematologic malignancies.